Newton D W, Rogers A G, Becker C H, Torosian G
Am J Hosp Pharm. 1975 Sep;32(9):912-7.
The stability and the behavior of patent blue (Alphazurine 2G) dye in a vehicle such as lidocaine hydrochloride injection were studied with regard to medication orders which may be prepared by hospital pharmacists. The patent blue family of dyes are sulfonated diaminotriphenylmethane, vital, acid dyes which have been used as diagnostic aids in both lymphography and burn debridement. A literature review, including some toxicological information, is presented. The occurrence of the sodium salt form and the equilibrium solubility of the patent blue sample studied are reported. Some implications of patent blue injections include: Clinical literature reports of toxicities, the unapproved status of patent blue by the Food and Drug Administration, results of stability studies, and the formation of viscid, water-insoluble precipitates of patent blue in combination with lidocaine hydrochloride. The extemporaneous preparation and subsequent use of parenteral prescriptions of patent blue dye in vehicles containing lidocaine hydrochloride and methylparaben are not recommended.
针对医院药剂师可能开具的医嘱,研究了专利蓝(阿尔发天蓝2G)染料在诸如盐酸利多卡因注射液等载体中的稳定性和行为。专利蓝染料家族是磺化二氨基三苯甲烷类活性酸性染料,已被用作淋巴造影和烧伤清创的诊断辅助剂。本文呈现了一篇文献综述,包括一些毒理学信息。报告了所研究专利蓝样品的钠盐形式的出现情况及其平衡溶解度。专利蓝注射液的一些影响包括:毒性的临床文献报告、食品药品监督管理局对专利蓝的未批准状态、稳定性研究结果,以及专利蓝与盐酸利多卡因结合形成粘稠的水不溶性沉淀物。不建议临时配制并随后使用含盐酸利多卡因和对羟基苯甲酸甲酯的载体中专利蓝染料的肠胃外处方。